Part of the session: EP-38 - Preclinical Studies -> Preclinical Studies -> Preclinical Therapy
| e-Poster Area

POSTER SECTIONS Coverpage Aim Materials & Methods Results Conclusion Disclosure 1 - Holding a Position (for details click on „i“) Disclosure 2 – Receiving Support (for details click on „i“) Disclosure 3 – Holding Property (for details click on „i“) Disclosure 4 – Having written Articles (for details click on „i“) References

EANM 20 / EP-294
A rat preliminary study on medication-related osteonecrosis of the jaw

Congress:	EANM 20
Poster No.:	EP-294
Type:	Scientific e-Poster
Keywords:	Preclinical Studies -> Preclinical Studies -> Preclinical Therapy, 8. Radionuclide Therapy & Dosimetry, 801 Preclinical Studies (Animal & In Vitro),
Authors:	F. M. Ribeiro¹, M. Laranjo², P. M. Encarnação¹, C. M. Marto³, R. Santos⁴, A. Paula³, A. I. Santos³, A. L. Silva¹, R. Oliveira⁵, N. Lima³, I. F. Castro⁶, N. Pereira⁴, P. M. Correia¹, M. Piñeiro⁴, G. F. S. Figueiredo¹, E. Carrilho³, T. Pinho e Melo⁴, M. F. Botelho², M. Marques-Ferreira³, J. F. Veloso¹; ¹Institute for Nanostructures, Nanomodelling and Nanofabrication (i3N), University of Aveiro, Aveiro, PORTUGAL, ²Institute of Biophysics, Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, ³Institute for Clinical and Biomedical Research (iCBR) Area of Environment Genetics and Oncobiology (CIMAGO), Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, PORTUGAL, ⁴Faculty of Sciences and Technology, University of Coimbra, Coimbra, PORTUGAL, ⁵Pathology Service, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, PORTUGAL, ⁶RI-TE, Radiation Imaging Technologies Lda, Ílhavo, PORTUGAL

Aim

Osteonecrosis of the jaw (ONJ) incidence has been reported as 0.004-28%, varying significantly according to the drug, dose, route of administration, and study design [1-3]. Multiple medication-related, demographic, systemic, genetic, and local risk factors are believed to cause ONJ [4-5]. Its development can be spontaneous, although invasive procedures such as tooth extraction can increase the incidence [6-7]. Medication-related osteonecrosis of the jaw (MRONJ) is characterized by progressive...

Materials & Methods

A previously validated MRONJ animal model was used [10]. Wistar female rats (10-weeks, 180-220 g) were administered with Zoledronate (Zol) (0.1 mg/kg) for 8 weeks, to induce ONJ. At week 4, the first upper right molar was extracted and, 72 hours before this procedure, rats were medicated with PS. Since photodynamic therapy (PDT) activates PS, the animals were randomly divided into two groups to ascertain the action of PS over ONJ: group 1, animals not submitted to PDT; group 2, animals...

Results

The easyPET.3D images, for group 1 (without PDT, rat B in Figure 1), showed a similar 18 F-FDG uptake compared to control (rat A in Figure 1), proving that PS remained inactive. For group 2 (with PDT, rat C in Figure 1), PET data showed an increase of tracer uptake, focal and unilateral matching the site of tooth extraction, therefore indicating the PS activation by the PDT. PS effect on ONJ was reflected by the higher metabolic activity of soft tissues. This study has not yet been completed,...

Conclusion

This pilot results, obtained with 18 F-FDG PET imaging in the selected rat model, by revealing the activation of PS with PDT, suggest that PS is a potential treatment for MRONJ. Further PET studies will be performed with 18 F-NaF to assess the effect of PS directly over bone necrosis induced by Zol.

Disclosure 1 - Holding a Position (for details click on „i“)

I. F. Castro/Managing Director/RI-TE Lda.

Disclosure 2 – Receiving Support (for details click on „i“)

Nothing to disclose.

Disclosure 3 – Holding Property (for details click on „i“)

A. L. Silva, I. F. Castro, P. M. Correia, J. F. Veloso/co-inventors PCT/IB2016/051487 patent/RI-TE shareholders.

Disclosure 4 – Having written Articles (for details click on „i“)

Nothing to disclose.

References

[1] Boonyapakorn T et al., Oral Oncol. 2008, 44: 857e869. [2] Malden N and Lopes V, J Bone Miner Metab. 2012, 30: 171e182. [3] Bodem JP et al., J Craniomaxillofac Surg. 2015, 43: 510e514. [4] Reid IR et al., Bone. 2007, 41: 318e320. [5] Ruggiero SL et al., J Oral Maxillofac Surg. 2014, 72: 1938e1956. [6] Senel FC et al., Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010, 109: 385e391. [7] Barba-Recreo P et al., J Craniomaxillofac Surg. 2014, 42: 744e750. [8] Pereira N. et al., Eur J Med...

POSTER ACTIONS ▪ Add bookmark ▪ Contact presenter

SHARE THIS POSTER

2 clicks for more privacy: On the first click the button will be activated and you can then share the poster with a second click.

Thematically related posters

EANM 20 / EP-289

Preclinical evaluation of targeted alpha therapy using ²²⁵Ac-DOTA-E[c(RGDfK)]₂ for pancreatic cancer

M. Yoshimoto¹, K. Washiyama², Y. Yoshii³, K. Ohnuki¹, H. Fujii¹; ¹Division of Functional Imaging, EPOC, National. Cancer Center, Kashiwa, JAPAN, ²Advanced Clinical Research Center, Fukushima Medical University, Fukushima, JAPAN, ³National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, JAPAN

EANM 20 / EP-290

Size-controlled ²²⁴Ra-labelled calcium carbonate microparticles against peritoneal carcinomatosis

R. G. Li¹, T. Bønsdorff², I. S. Jorstad², K. Lindland², S. K. Tonstad², Ø. S. Bruland¹, S. Westrøm², R. H. Larsen²; ¹Institute of Clinical Medicine, University of Oslo, Oslo, NORWAY, ²Oncoinvent AS, Oslo, NORWAY

EANM 20 / EP-291

Feasibility of MR-guided intratumoral treatment with Holmium-166 microspheres in a brain tumor model

N. Klaassen¹, N. C. Morsink², M. de Vries³, J. J. van den Dobbelsteen³, M. Boswinkel¹, S. A. van Nimwegen², J. F. W. Nijsen¹; ¹Radboud university medical center, Radboud Institute for Molecular Life Sciences, Department of Radiology, Nuclear Medicine and Anatomy, Nijmegen, NETHERLANDS, ²Utrecht University, Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht, NETHERLANDS, ³Delft University of Technology, Department of BioMechanical Engineering, Delft, NETHERLANDS

EANM 20 / EP-292

Conjugation of GRPR-targeting antagonist RM26 to albumin-binding domain extends antagonist's blood circulation and residence in tumours

A. Abouzayed¹, S. S. Rinne¹, F. Wadeea¹, H. Tano², Á. Nagy², A. E. Karlström², V. Tolmachev¹, A. Orlova¹; ¹Uppsala University, Uppsala, SWEDEN, ²KTH Royal Institute of Technology, Stockholm, SWEDEN

Other posters by the same authors

EANM 20 / EP-266

Quercetin as a potential psychotherapeutic agent in a mouse model with acute exposure to cocaine: a preclinical PET study

F. M. Ribeiro¹, C. Nicolucci², M. Lapo Pais³, A. I. Santos⁴, P. M. Encarnação¹, A. L. Silva¹, I. F. Castro⁵, P. M. Correia¹, V. I. Assunção¹, J. F. Veloso¹, D. Priolli²; ¹Institute for Nanostructures, Nanomedelling and Nanofabrication (i3N), University of Aveiro, Aveiro, PORTUGAL, ²Multidisciplinary Research Laboratory, São Francisco University, Bragança Paulista, BRAZIL, ³Faculty of Sciences and Technology, University of Coimbra, Coimbra, PORTUGAL, ⁴Institute for Clinical and Biomedical Research (iCBR), Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, PORTUGAL, ⁵Radiation Imaging Technologies Lda (RI-TE), Ílhavo, PORTUGAL

EANM 20 / EPS-110

Visual Vascular Score with 2-[¹⁸F]FDG: validation on a control sample

R. Ferreira, M. R. Victor, S. Carmona, A. I. Santos; Hospital Garcia de Orta, Almada, PORTUGAL

EANM 20 / TEPS-37

Computer-aided detection of cancer on PET/CT images based on anomaly detection using GAN-based deep learning

T. Maeda¹, M. Haga¹, T. Hara¹, T. Katafuchi², X. Zhou¹, M. Matsusako³, S. Ito⁴, M. Kato⁴, A. Yamada⁵, H. Fujita¹; ¹Gifu University, Gifu, JAPAN, ²Gifu University of Medical Science, Seki, JAPAN, ³St. Luke’s International Hospital, Tokyo, JAPAN, ⁴Daiyukai General Hospital, Ichinomiya, JAPAN, ⁵Shinshu University, Matsumoto, JAPAN

EANM 20 / TEPS-38

Use of artifical neural network for the diagnosis of myocardial ischemia :Comparison of imaging diagnosis between two devices in the clinical conditions

M. Kano¹, D. Ogura¹, T. Ino², T. Toyama³, K. Koyama¹; ¹Gunma Prefectural Cardiovascular Center, Maebashi-shi, Gumma-ken, JAPAN, ²Gunma Prefectural Phychiatric Medical Center, Isesaki-shi, Gumma-ken, JAPAN, ³Toyama cardiovasculary Clinic, Maebashi-shi, Gumma-ken, JAPAN